Your browser doesn't support javascript.
loading
Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions.
Qureshi, O S; Rowley, T F; Junker, F; Peters, S J; Crilly, S; Compson, J; Eddleston, A; Björkelund, H; Greenslade, K; Parkinson, M; Davies, N L; Griffin, R; Pither, T L; Cain, K; Christodoulou, L; Staelens, L; Ward, E; Tibbitts, J; Kiessling, A; Smith, B; Brennan, F R; Malmqvist, M; Fallah-Arani, F; Humphreys, D P.
Afiliação
  • Qureshi OS; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Rowley TF; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Junker F; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Peters SJ; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Crilly S; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Compson J; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Eddleston A; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Björkelund H; Ridgeview Diagnostics AB, Uppsala Science Park, SE75183, Uppsala, Sweden.
  • Greenslade K; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Parkinson M; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Davies NL; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Griffin R; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Pither TL; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Cain K; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Christodoulou L; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Staelens L; UCB Biopharma Sprl., Chemin du Foriest, Braine l'Alleud, Belgium.
  • Ward E; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Tibbitts J; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Kiessling A; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Smith B; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Brennan FR; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Malmqvist M; Ridgeview Diagnostics AB, Uppsala Science Park, SE75183, Uppsala, Sweden.
  • Fallah-Arani F; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK.
  • Humphreys DP; UCB Pharma, 216 Bath Road, Slough, SL1 3WE, UK. david.humphreys@ucb.com.
Sci Rep ; 7(1): 17049, 2017 12 06.
Article em En | MEDLINE | ID: mdl-29213127
Engagement of Fcγ-receptors triggers a range of downstream signalling events resulting in a diverse array of immune functions. As a result, blockade of Fc-mediated function is an important strategy for the control of several autoimmune and inflammatory conditions. We have generated a hexameric-Fc fusion protein (hexameric-Fc) and tested the consequences of multi-valent Fcγ-receptor engagement in in vitro and in vivo systems. In vitro engagement of hexameric-Fc with FcγRs showed complex binding interactions that altered with receptor density and triggered the internalisation and degradation of Fcγ-receptors. This caused a disruption of Fc-binding and phagocytosis. In vivo, in a mouse ITP model we observed a short half-life of hexameric-Fc but were nevertheless able to observe inhibition of platelet phagocytosis several days after hexameric-Fc dosing. In cynomolgus monkeys, we again observed a short half-life, but were able to demonstrate effective FcγR blockade. These findings demonstrate the ability of multi-valent Fc-based therapeutics to interfere with FcγR function and a potential mechanism through which they could have a sustained effect; the internalisation and degradation of FcγRs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos Fc das Imunoglobulinas / Receptores de IgG Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos Fc das Imunoglobulinas / Receptores de IgG Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article